The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients

Clinical Nephrology

Volumn 72, Issue 1, 2009, Pages 5-14

  Herberth, J ^a   Monier Faugere, M C ^a   Mawad, H W ^a   Branscum, A J ^a   Herberth, Z ^a   Wang, G ^a   Cantor, T ^b   Malluche, H H ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Scantibodies Laboratory Inc   (United States)

Author keywords

Alkaline phosphatase; Bone turnover; End stage renal disease; K DOQI; Parathyroid hormone; PTH assays; Renal osteodystrophy

Indexed keywords

ALKALINE PHOSPHATASE; PARATHYROID HORMONE; BIOLOGICAL MARKER;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE BIOPSY; BONE TURNOVER; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; FEMALE; HISTOPATHOLOGY; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY; BIOPSY; BLOOD; CHI SQUARE DISTRIBUTION; CHRONIC KIDNEY FAILURE; MIDDLE AGED; NONPARAMETRIC TEST; PREDICTION AND FORECASTING; REGISTER; RENAL OSTEODYSTROPHY; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BIOPSY; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PREDICTIVE VALUE OF TESTS; REGISTRIES; RENAL OSTEODYSTROPHY; STATISTICS, NONPARAMETRIC;

EID: 70349239454     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp72005     Document Type: Article

References (38)

1. Barreto FC, Barreto DV, Moyses RM, Neves KR, Canziani ME, Draibe SA, Jorgetti V, Carvalho AB. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008; 73: 771-777.
2. Berson SA, Yalow RS. Immunochemical heterogeneity of parathyroid hormone in plasma. J Clin Endocrinol Metab. 1968; 28: 1037-1047.
3. Bervoets AR, Spasovski GB, Behets GJ, Dams G, Polenakovic MH, Zafirovska K, Van Hoof VO, De Broe ME, D'Haese PC. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003; 41: 997-1007.
4. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab. 1996; 81: 3923-3929.
5. Brossard JH, Yamamoto LN, D'Amour P. Parathyroid hormone metabolites in renal failure: bioactivity and clinical implications. Semin Dial. 2002; 15: 196-201.
6. Brown RC, Aston JP, Weeks I, Woodhead JS. Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay. J Clin Endocrinol Metab. 1987; 65: 407-414.
7. Cantor T. Parathyroid hormone assay drift: an unappreciated problem in dialysis patient management. Semin Dial. 2005; 18: 359-564.
8. Cantor T, Yang Z, Caraiani N, Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem. 2006; 52: 1771-1776.
9. Donadio C, Ardini M, Lucchesi A, Donadio E, Cantor T. Parathyroid hormone and large related C-terminal fragments increase at different rates with worsening of renal function in chronic kidney disease patients. A possible indicator of bone turnover status? Clin Nephrol 2007; 67: 131-139.
10. Fahrleitner-Pammer A, Herberth J, Browning SR, Obermayer-Pietsch B, Wirnsberger G, Holzer H, Dobnig H, Malluche HH. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res. 2008; 23(11): 1850-1858.
11. Fischer JA, Binswanger U, Dietrich FM. Human parathyroid hormone. Immunological characterization of antibodies against a glandular extract and the synthetic amino-terminal fragments 1-12 and 1-34 and their use in the determination of immunoreactive hormone in human sera. J Clin Invest. 1974; 54: 1382-1394.
12. Herberth J, Fahrleitner-Pammer A, Obermayer-Pietsch B, Krisper P, Holzer H, Malluche HH, Dobnig H. Changes in total parathyroid hormone (pth), pth-(1-84) and large c-pth fragments in different stages of chronic kidney disease. Clin Nephrol. 2006; 65: 328-334.
13. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995; 33: 166-174.
14. Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, Massart C, Moe SM, Monge M, Souberbielle JC. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis. 2008; 51: 987-995.
15. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42: S1-201.
16. Langub MC, Monier-Faugere MC, Wang G, Williams JP, Koszewski NJ, Malluche HH. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology. 2003; 144: 1135-1138.
17. Malluche HH, Faugere MC. Atlas of mineralized bone histology. New York: Karger; 1986.
18. Malluche HH, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int. 1990; 38: 193-211.
19. Malluche HH, Ritz E, Lange H, Kutschera K, Hodgson M, Seiffert U, Schoeppe W. Bone histology in incipient and advanced renal failure. Kidney Int. 1976; 9: 355-362.
20. Malluche HH, Meyer W, Sherman D, Massry SG. Quantitative bone histology in 84 normal American subjects. Micromorphometric analysis and evaluation of variance in iliac bone. Calcif Tissue Int. 1982; 34: 449-455.
21. Malluche HH, Faugere MC, Fanti P, Price PA. Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int. 1984; 26: 869-874.
22. Malluche HH, Monier-Faugere MC. Renal osteodystrophy: what's in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol. 2006; 65: 235-242.
23. Malluche HH, Monier-Faugere MC. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol. 1994; 4: 1631-1642.
24. Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG. An assessment of cinacalcet HCl effects on bone histology in dialysis patientswith secondary hyperparathyroidism. Clin Nephrol. 2008; 69: 269-278.
25. Manning RM, Hendy GN, Papapoulos SE, O'Riordan JL. Development of homologous immunological assays for human parathyroid hormone. J Endocrinol. 1980; 85: 161-170.
26. Martin KJ, Hruska KA, Freitag JJ, Klahr S, Slatopolsky E. The peripheral metabolism of parathyroid hormone. N Engl J Med. 1979; 301: 1092-1098.
27. Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, Malluche HH, McCarthy JT, Massry SG, Mehls O, Salusky IB, Silver JM, Smogorzewski MT, Slatopolsky EM, McCann L. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004; 43: 558-565.
28. Mayer GP, Keaton JA, Hurst JG, Habener JF. Effects of plasma calcium concentration on the relative proportion of hormone and carboxyl fragments in parathyroid venous blood. Endocrinology. 1979; 104: 1778-1784.
29. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69: 1945-1953.
30. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH. Improved assessment of bone turnover by the PTH-(1-84)/ large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001; 60: 1460-1468.
31. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nazawa-Ung K, Kim LY, H.T. K, Wang CA, Potts JT, Segre GV. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem. 1988; 33: 1364-1367.
32. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995; 26: 622-631.
33. Ritz E, Krempien B, Mehls O, Malluche H. Skeletal abnormalities in chronic renal insufficiency before and during maintenance hemodialysis. Kidney Int. 1973; 4: 116-127.
34. Segre GV, Niall HD, Sauer RT, Potts JT, Jr. Edman degradation of radioiodinated parathyroid hormone: application to sequence analysis and hormone metabolism in vivo. Biochemistry. 1977; 16: 2417-2427.
35. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006; 70: 345-350.
36. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int. 1999; 55: 2141-2156.
37. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis. 1995; 26: 836-844.
38. Whitham KM, Milford-Ward A. External quality assessment of bone metabolism marker assays. initial experiences in a UK NEQAS programme. Clin Chem Lab Med. 2000; 38: 1121-1124.